Breaking News

NextGen 2.0 helmets on the way to security forces across DAF > Air Force > Article Display Joint Statement on the U.S.-Romanian Bilateral Defense Relationship > U.S. Department of Defense > Release Deputy Secretary Graves to Travel to Bucharest, Romania for International Telecommunication Union Plenipotentiary Conference President Joseph R. Biden, Jr. Approves Emergency Declaration for Florida Puerto Rico Residents Encouraged to Register for Federal Assistance News Release – Attorney General Moody Expands Price Gouging Hotline Statewide as Tropical Storm Ian Intensifies FEMA Continues Hurricane Fiona Response Efforts: Sept. 24 Updates President Joseph R. Biden, Jr. Approves Major Disaster Declaration for Alaska

Issued: London, UK

GSK delivers sales growth, improved cash flow and sustained pipeline progression in Q3

View full Q3 2016 results (PDF)

  • Group sales £7.5 billion, +8% CER, with continued growth across all three businesses
  • New product sales £1.21 billion +79% (Q1 2016: £821 million; Q2 2016: £1.05 billion) driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and Meningitis vaccines (Bexsero, Menveo)
  • Improved operating leverage driven by sales growth, delivery of restructuring and integration benefits and continued tight control of costs including targeted reinvestments
  • Q3 total earnings per share 16.6p, -1% CER, impacted by charges resulting from increases in valuations of Consumer Healthcare and HIV businesses
  • Q3 core earnings per share 32p, +12% CER
  • Continue to expect 2016 core EPS percentage growth to be 11-12% CER
  • Q3 net cash inflow from operations of £1.8 billion (Q3 2015: £0.5 billion)
  • 19p dividend declared for Q3.  Continue to expect 80p for FY 2016 and 2017
  • Sustained delivery in R&D pipeline

Full details available in the quarterly results section of this website.

Source link